Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Mesa Laboratories (MLAB) Other Operating Expenses (2016 - 2025)

Mesa Laboratories (MLAB) has disclosed Other Operating Expenses for 16 consecutive years, with $10.0 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses fell 4.44% to $10.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $42.0 million through Dec 2025, down 86.68% year-over-year, with the annual reading at $41.7 million for FY2025, 86.69% down from the prior year.
  • Other Operating Expenses hit $10.0 million in Q4 2025 for Mesa Laboratories, up from $9.8 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $284.8 million in Q1 2024 to a low of -$8.4 million in Q4 2021.
  • Historically, Other Operating Expenses has averaged $20.2 million across 5 years, with a median of $9.8 million in 2023.
  • Biggest five-year swings in Other Operating Expenses: plummeted 392.17% in 2021 and later soared 2812.31% in 2024.
  • Year by year, Other Operating Expenses stood at -$8.4 million in 2021, then soared by 106.62% to $558000.0 in 2022, then soared by 1644.98% to $9.7 million in 2023, then increased by 7.32% to $10.4 million in 2024, then fell by 4.44% to $10.0 million in 2025.
  • Business Quant data shows Other Operating Expenses for MLAB at $10.0 million in Q4 2025, $9.8 million in Q3 2025, and $10.9 million in Q2 2025.